Quoin pharmaceuticals provides corporate update and announces second quarter 2022 financial results

Initiates clinical trial evaluating lead product candidate, qrx003 for netherton syndrome expands number of commercial partnerships to eight, covering 60 countries signs research agreement to develop a product for the treatment of scleroderma closes $16.8 million public offering, with net proceeds of approximately $15.0 million

QNRX Ratings Summary

QNRX Quant Ranking